The FDA is informing patients, caregivers, and health care providers about reported differences in complication rates among Acellular Dermal Matrix (ADM) products in implant-based breast reconstruction.
Read more: Acellular Dermal Matrix (ADM) Products Used in Implant-Based Breast Reconstruction Differ in Complication Rates: FDA Safety Communication